Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478

Biochemical Pharmacology

Volumn 77, Issue 5, 2009, Pages 781-793

  Shi, Zhi ^a,b   Tiwari, Amit K ^a   Shukla, Suneet ^c   Robey, Robert W ^c   Kim, In Wha ^c   Parmar, Smitaben ^a   Bates, Susan E ^c   Si, Qiu Sheng ^d   Goldblatt, Curtis S ^d   Abraham, Ioana ^a   Fu, Li Wu ^b   Ambudkar, Suresh V ^c   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Department of Pharmaceutical Care Services   (United States)

Author keywords

ABCB1; ABCG2; EGFR tyrosine kinase inhibitor; Multidrug resistance

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; COLCHICINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUORESCENT DYE; IODINE 125; IODOARYLAZIDOPRAZOSIN I 125; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PRAZOSIN; TRITIUM; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE;

ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MEMBRANE VESICLE; MOLECULAR INTERACTION; MULTIDRUG RESISTANCE; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PROTEIN KINASE INHIBITORS; TRITIUM; TYRPHOSTINS;

EID: 59949101954     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.11.007     Document Type: Article

References (42)

1. Levitzki A., and Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 267 (1995) 1782-1788
2. Arteaga C.L., Ramsey T.T., Shawver L.K., and Guyer C.A. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J Biol Chem 272 (1997) 23247-23254
3. Gazit A., Chen J., App H., McMahon G., Hirth P., Chen I., et al. Tyrphostins IV--highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines. Bioorg Med Chem 4 (1996) 1203-1207
4. Bridges A.J. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Curr Med Chem 6 (1999) 825-843
5. Partik G., Hochegger K., Schorkhuber M., and Marian B. Inhibition of epidermal-growth-factor-receptor-dependent signalling by tyrphostins A25 and AG1478 blocks growth and induces apoptosis in colorectal tumor cells in vitro. J Cancer Res Clin Oncol 125 (1999) 379-388
6. Shushan A., Rojansky N., Laufer N., Klein B.Y., Shlomai Z., Levitzki R., et al. The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth. Hum Reprod 19 (2004) 1957-1967
7. Zhu X.F., Liu Z.C., Xie B.F., Li Z.M., Feng G.K., Yang D., et al. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett 169 (2001) 27-32
8. Nagane M., Levitzki A., Gazit A., Cavenee W.K., and Huang H.J. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A 95 (1998) 5724-5729
9. Lei W., Mayotte J.E., and Levitt M.L. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells. Anticancer Res 19 (1999) 221-228
10. Nagane M., Narita Y., Mishima K., Levitzki A., Burgess A.W., Cavenee W.K., et al. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg 95 (2001) 472-479
11. Johns T.G., Luwor R.B., Murone C., Walker F., Weinstock J., Vitali A.A., et al. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc Natl Acad Sci U S A 100 (2003) 15871-15876
12. Lee F.T., Mountain A.J., Kelly M.P., Hall C., Rigopoulos A., Johns T.G., et al. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A"-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. Clin Cancer Res 11 (2005) 7080s-7086s
13. Ellis A.G., Doherty M.M., Walker F., Weinstock J., Nerrie M., Vitali A., et al. Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochem Pharmacol 71 (2006) 1422-1434
14. Akiyama S., Fojo A., Hanover J.A., Pastan I., and Gottesman M.M. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet 11 (1985) 117-126
15. Taguchi Y., Yoshida A., Takada Y., Komano T., and Ueda K. Anti-cancer drugs and glutathione stimulate vanadate-induced trapping of nucleotide in multidrug resistance-associated protein (MRP). FEBS Lett 401 (1997) 11-14
16. Robey R.W., Honjo Y., Morisaki K., Nadjem T.A., Runge S., Risbood M., et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89 (2003) 1971-1978
17. Cornwell M.M., Gottesman M.M., and Pastan I.H. Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells. J Biol Chem 261 (1986) 7921-7928
18. Ramachandra M., Ambudkar S.V., Chen D., Hrycyna C.A., Dey S., Gottesman M.M., et al. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry 37 (1998) 5010-5019
19. Kerr K.M., Sauna Z.E., and Ambudkar S.V. Correlation between steady-state ATP hydrolysis and vanadate-induced ADP trapping in Human P-glycoprotein. Evidence for ADP release as the rate-limiting step in the catalytic cycle and its modulation by substrates. J Biol Chem 276 (2001) 8657-8664
20. Shi Z., Liang Y.J., Chen Z.S., Wang X.W., Wang X.H., Ding Y., et al. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther 5 (2006) 39-47
21. Aoki S., Chen Z.S., Higasiyama K., Setiawan A., Akiyama S., and Kobayashi M. Reversing effect of agosterol A, a spongean sterol acetate, on multidrug resistance in human carcinoma cells. Jpn J Cancer Res 92 (2001) 886-895
22. Chen Z.S., Robey R.W., Belinsky M.G., Shchaveleva I., Ren X.Q., Sugimoto Y., et al. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 63 (2003) 4048-4054
23. Shukla S., Robey R.W., Bates S.E., and Ambudkar S.V. The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry 45 (2006) 8940-8951
24. Sauna Z.E., and Ambudkar S.V. Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. Proc Natl Acad Sci U S A 97 (2000) 2515-2520
25. Honjo Y., Hrycyna C.A., Yan Q.W., Medina-Perez W.Y., Robey R.W., van de Laar A., et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61 (2001) 6635-6639
26. Mogi M., Yang J., Lambert J.F., Colvin G.A., Shiojima I., Skurk C., et al. Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J Biol Chem 278 (2003) 39068-39075
27. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., and Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39 (1999) 361-398
28. Meyer zu Schwabedissen H.E., Grube M., Dreisbach A., Jedlitschky G., Meissner K., Linnemann K., et al. Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP). Drug Metab Dispos 34 (2006) 524-533
29. Germann U.A., Chambers T.C., Ambudkar S.V., Licht T., Cardarelli C.O., Pastan I., et al. Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem 271 (1996) 1708-1716
30. Nakamura Y., Oka M., Soda H., Shiozawa K., Yoshikawa M., Itoh A., et al. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 65 (2005) 1541-1546
31. Stewart C.F., Leggas M., Schuetz J.D., Panetta J.C., Cheshire P.J., Peterson J., et al. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64 (2004) 7491-7499
32. Leggas M., Panetta J.C., Zhuang Y., Schuetz J.D., Johnston B., Bai F., et al. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 66 (2006) 4802-4807
33. Yanase K., Tsukahara S., Asada S., Ishikawa E., Imai Y., and Sugimoto Y. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 3 (2004) 1119-1125
34. Yang C.H., Huang C.J., Yang C.S., Chu Y.C., Cheng A.L., Whang-Peng J., et al. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 65 (2005) 6943-6949
35. Kitazaki T., Oka M., Nakamura Y., Tsurutani J., Doi S., Yasunaga M., et al. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49 (2005) 337-343
36. Erlichman C., Boerner S.A., Hallgren C.G., Spieker R., Wang X.Y., James C.D., et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 61 (2001) 739-748
37. Elkind N.B., Szentpetery Z., Apati A., Ozvegy-Laczka C., Varady G., Ujhelly O., et al. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 65 (2005) 1770-1777
38. Shi Z., Peng X.X., Kim I.W., Shukla S., Si Q.S., Robey R.W., et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 67 (2007) 11012-11020
39. Zhuang Y., Fraga C.H., Hubbard K.E., Hagedorn N., Panetta J.C., Waters C.M., et al. Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. Cancer Res 66 (2006) 11305-11313
40. Cusatis G., Gregorc V., Li J., Spreafico A., Ingersoll R.G., Verweij J., et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 98 (2006) 1739-1742
41. Li J., Cusatis G., Brahmer J., Sparreboom A., Robey R.W., Bates S.E., et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 6 (2007) 432-438
42. Dai C.L., Tiwari A.K., Wu C.P., Su X.D., Wang S.R., Liu D.G., et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 68 (2008) 7905-7914